Hemostemix Inc. (CVE:HEM – Get Free Report) shares fell 19.4% during mid-day trading on Thursday . The company traded as low as C$0.14 and last traded at C$0.15. 519,694 shares were traded during mid-day trading, a decline of 1% from the average session volume of 526,987 shares. The stock had previously closed at C$0.18.
Hemostemix Stock Down 19.4 %
The stock has a market capitalization of C$21.13 million, a P/E ratio of -4.23 and a beta of 0.20. The company has a debt-to-equity ratio of -55.07, a current ratio of 0.04 and a quick ratio of 0.48. The firm has a 50-day simple moving average of C$0.20 and a 200 day simple moving average of C$0.12.
About Hemostemix
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Read More
- Five stocks we like better than Hemostemix
- Are Penny Stocks a Good Fit for Your Portfolio?
- Should You Hold Nvidia Stock for the Long Haul or Trade It?
- What Does Downgrade Mean in Investing?
- Humana Gains Despite Medicare Advantage Losses—What’s the Catch?
- How to Calculate Inflation Rate
- Buybacks Galore: 3 Mega-Caps Just Approved Billions in Buybacks
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
